Biosimilars: What investors need to know

Are the biotech and pharmaceutical industries entering a new phase of heightened competition? Health care appears to be on the cusp of a dynamic transformation. In March 2015, the U.S. approved the use of biosimilars, an exciting new treatment that may slash costs for patients and providers alike.

Biosimilar treatments are essentially replicas, or copycats, of biologic drugs – the most complex, exotic and expensive specialty drugs on the market. Since they may be significantly lower in cost, biosimilars may make it possible for more people to access life-saving or live-improving treatments.

In their recent Global Insight special report The Biosimilars Revolution, RBC Wealth Management’s Portfolio Advisory Group analysts outline what you need to know to make well informed portfolio decisions about biosimilars. To request a copy of the report please contact your RBC Wealth Management financial advisor or use the advisor locator tool to find an advisor near you.

Important disclosure information about Royal Bank of Canada (RBC) and RBC Capital Markets, LLC